The Impact of Modified Wheat Bran on Carbohydrate Fermentation in the Colon in Healthy and Obese Subjects
Phase 1
Completed
- Conditions
- HealthyObese
- Interventions
- Dietary Supplement: Wheat branDietary Supplement: Placebo
- Registration Number
- NCT02796989
- Lead Sponsor
- KU Leuven
- Brief Summary
During this project the effect of modified wheat bran on colon health and systemic health will be evaluated in a long-term intervention study in healthy and obese subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Aged between 18 and 65 years old
- BMI between 18 and 25 kg/m² OR higher than 30 kg/m²
- Regular diet
- Not dieting
Exclusion Criteria
- Use of antibiotics in the month preceding the study
- Diabetes Type 1 or 2
- Abdominal surgery (except from appendectomy)
- Use of medication that affects the gastrointestinal tract during the last 2 weeks prior to the study including spasmolytics, anti-diarrhoea medication, anti-constipation medication
- Use of pre- or probiotic supplements in the month preceding the study
- Chronic gastrointestinal diseases, such as inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel disease...
- Pregnancy or lactation
- Blood donation in the last 3 months
- Abnormal Hb-level (Standard range between 14 and 18 g/dL for men and between 12 and 16 g/dL for women)
- Participation in clinical studies involving radiation exposure in the past year
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Healthy - Wheat Bran Wheat bran Wheat bran 20 g each day Healthy - Placebo Placebo Placebo 20 g each day Obese - Wheat bran Wheat bran Wheat bran 20 g each day Obese - Placebo Placebo Placebo 20 g each day
- Primary Outcome Measures
Name Time Method The incremental plasma short-chain fatty acid concentrations will be measured using GC-FID after an intervention with wheat bran/placebo 1 month
- Secondary Outcome Measures
Name Time Method Total gastrointestinal transit time 1 month Gut permeability using 51-Cr-EDTA 1 month Changes in gut microbiota before and after the intervention using 16S rRNA sequencing 1 month Changes in glucose levels (mg/dL) 1 month Changes in cholesterol levels (mg/dL) 1 month Changes in free fatty acids levels (mmol/L) 1 month Changes in triglyceride levels (mg/dL) 1 month Changes in insulin levels (pmol/L) 1 month Changes in metabolite patterns in the feces before and after the intervention using gas chromatography coupled to mass spectrometry 1 month
Trial Locations
- Locations (1)
KU Leuven
🇧🇪Leuven, Vlaams-Brabant, Belgium